A strategic change towards Olympus's medical business, and particularly therapeutic procedures, has reignited growth. Next up: acquisitions.
Data from Gilead's Atlas combination trial in Nash could point to a way forward, while Roche and Ionis are hoping to confirm earlier signals seen with a…
Alnylam unveils a novel pricing strategy for its second RNAi launch, which was greenlit by the US regulator with notable speed.
Innovate combines with RDD, but the success of the takeover relies in large part on a project for coeliac disease.
Genfit's quiet delay means it will be five years since a Nash failure before investors find out whether pressing on into phase III was worth it.
Reneuron is set to release further data with its hRPC stem cell therapy in retinitis pigmentosa, while Provention Bio aims to target Crohn’s early with PRV-6527.
With the buyout of Sitari Pharmaceuticals, Glaxosmithkline becomes only the second major drug maker to have an interest in coeliac disease.
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
The company’s Enigma study in an orphan digestive tract disease points a way to approval, notwithstanding the company’s statistical analysis method.